LB Pharmaceuticals Inc: LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with Schizophrenia

LB-102 has potential to be the first benzamide approved for schizophrenia in the U.S. NOVA-2 trial to enroll approximately 460 patients Primary endpoint to evaluate change in PANSS total score at week ...

AD/PD 2026: J&Js anti-tau drug posdinemab fails in early Alzheimer’s disease

J&J was keen to highlight that these trial results do not invalidate tau as a therapeutic target for Alzheimer’s disease; the ...

Scientists have found a link between sleep disorders and the risk of dementia

With age, sleep becomes more shallow and intermittent — this is a natural process associated with changes in brain function ...
TMCnet

Artelo Biosciences Expansion into $16.3B Glaucoma Market, Via Fully Funded Study, Highlights Multi-Platform Pipeline Strength

Artelo Biosciences, Inc. (NASDAQ: ARTL) is drawing increased attention following its expansion into the $16.3 billion ...

Denali Therapeutics Inc.: Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)

First new FDA-approved treatment option in nearly 20 years for families living with this rare lysosomal storage diseaseFirst FDA-approved medicine in emerging new class of biotherapeutics that leverag ...